Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.35 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15348176 | 0.95 | NPC1 (0.49) | NPC1MITFLMNATP53RAB9A | |
| SCHEMBL11613552 | 0.89 | NPC1 (0.53) | NPC1MITFLMNATP53RAB9A | |
| SCHEMBL9394796 | 0.82 | L3MBTL1 (0.51) | NPC1MITFLMNATP53RAB9A | |
| SCHEMBL9752675 | 0.82 | L3MBTL1 (0.51) | NPC1MITFLMNATP53RAB9A | |
| SCHEMBL9752571 | 0.81 | L3MBTL1 (0.50) | NPC1MITFLMNATP53RAB9A | |
| SCHEMBL9752728 | 0.81 | L3MBTL1 (0.50) | NPC1MITFLMNATP53RAB9A | |
| SCHEMBL9752719 | 0.81 | L3MBTL1 (0.50) | NPC1MITFLMNATP53RAB9A | |
| SCHEMBL6727933 | 0.79 | L3MBTL1 (0.47) | NPC1MITFLMNATP53RAB9A | |
| SCHEMBL9752595 | 0.78 | L3MBTL1 (0.55) | NPC1MITFLMNATP53RAB9A | |
| SCHEMBL2495415 | 0.78 | TP53 (0.45) | NPC1MITFLMNATP53RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771677-B2 | Immunomodulating urea azalides | ZOETIS SERVICES LLC (US) | 2023-10-03 | — | — | US | disclosed |
| US-11771677-B2 | Immunomodulating urea azalides | ZOETIS SERVICES LLC (US) | 2023-10-03 | — | — | US | disclosed |
| US-20210290591-A1 | IMMUNOMODULATING UREA AZALIDES | ZOETIS SERVICES LLC | 2021-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11771677-B2 | Immunomodulating urea azalides | ARG1, IL2, CD209 | NPC1 3229/4885MITF 1386/4885LMNA 4881/4885 |
| US-20210290591-A1 | IMMUNOMODULATING UREA AZALIDES | ARG1, IL2, CD209 | NPC1 3229/4885MITF 1386/4885LMNA 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.